Lilly Enters Psychedelic Realm Through $2.8bn AtaiBeckley Takeover
Click to view quick news summary (Spoiler)
Pharmaceutical giant Eli Lilly has acquired psychedelic drug developer AtaiBeckley in a $2.8 billion deal, securing advanced clinical assets targeting treatment-resistant depression and social anxiety disorder, including the Phase 3 candidate BPL-003.
Following an aggressive series of strategic deals throughout the first half of 2026, global pharmaceutical leader Eli Lilly has completed another major transaction — acquiring specialized psychedelic biotechnology firm AtaiBeckley in a multi-billion-dollar acquisition.
Under the agreed terms, Lilly will pay $2.8 billion in upfront cash to absorb AtaiBeckley’s pipeline of three clinical-stage neuro-psychiatric candidates. The centerpiece of the acquisition is BPL-003, an intranasally administered candidate targeting treatment-resistant depression (TRD).
BPL-003 is a synthetic formulation of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), chemically known as mebufotenin benzoate. The asset recently advanced into pivotal Phase III clinical trials after Phase IIa trial data demonstrated a statistically significant 19.0-point reduction in standardized depression rating scores from baseline following just two administered doses.
AtaiBeckley’s Clinical Asset Pipeline
While BPL-003 represents AtaiBeckley’s most clinically advanced drug candidate, the acquired portfolio includes two additional mid-stage development programs: VLS-01 and EMP-01.
Similar to BPL-003, VLS-01 is a DMT-derived therapeutic targeted at TRD. However, rather than utilizing nasal spray delivery, VLS-01 is formulated as an orally dissolving transmucosal film. This delivery system is designed to improve patient compliance and reduce administration challenges associated with nasal delivery platforms. VLS-01 is currently completing Phase II clinical evaluations.
The third asset, EMP-01, is an MDMA-based candidate under development for social anxiety disorder (SAD), which recently met primary safety and efficacy endpoints in a Phase IIa clinical trial.
AtaiBeckley was originally formed through the November 2025 merger of atai Life Sciences and Beckley Psytech, consolidating their respective clinical portfolios of novel psychedelic medicines. Under the acquisition agreement, AtaiBeckley shareholders remain eligible to receive up to an additional $1 billion in financial payouts through Contingent Value Rights (CVRs), contingent upon achieving specific clinical development and regulatory milestones.
Big Pharma Capital Expansion into Psychedelics
Lilly’s buyout of AtaiBeckley represents the pharmaceutical major’s first direct entry into psychedelic medicine. The move follows competitor AbbVie’s recent entry into the sector via a $1.2 billion licensing deal for Gilgamesh’s next-generation psychedelic candidate, bretisilocin.
Bibiochemical industry analysts at Jefferies noted that Lilly's acquisition confirms that "large pharmaceutical companies are increasingly committing capital to the psychedelic therapeutics field." This commercial shift coincides with robust clinical trial data from late-stage programs, including Compass Pathways’ psilocybin-based candidate COMP360, which demonstrated durable efficacy in TRD patient cohorts.
COMP360 could become the first classical psychedelic to earn regulatory clearance for a psychiatric indication, as the US Food and Drug Administration (FDA) is actively reviewing a New Drug Application (NDA) based on positive Phase III trial results.
Concurrently, Definium Therapeutics reported positive Phase III trial results for DT120, an LSD-based candidate evaluated for major depressive disorder (MDD), as it awaits readouts from a parallel Phase III study. Commenting on the competitive landscape, GlobalData neurology analyst Philippa Salter highlighted that candidates capable of delivering rapid therapeutic relief from single or infrequent doses offer a compelling clinical alternative for patients seeking to avoid chronic daily antidepressant regimens.
